NFL Biosciences Secures €500K Loan from Bpifrance for Phase 2 Trial Prep
Event summary
- NFL Biosciences received a €500,000 loan from Bpifrance to support Phase 2 clinical trial application for NFL-102.
- The loan is non-dilutive and was not initially anticipated in the company's financing plans.
- NFL-102 targets nicotine addiction by normalizing CREB activity, a key regulator of tobacco addiction.
- Phase 2 trial application for NFL-102 is expected in mid-2026.
The big picture
This loan underscores Bpifrance's continued support for innovative biopharmaceutical companies targeting addiction treatment. The focus on botanical drugs aligns with broader industry trends toward natural therapeutic solutions, particularly for global health challenges in low- and middle-income countries. NFL Biosciences' ability to secure non-dilutive financing highlights its strategic positioning in the addiction treatment space.
What we're watching
- Trial Timing
- Whether NFL Biosciences can maintain the mid-2026 timeline for Phase 2 trial application submission.
- Funding Strategy
- How this non-dilutive financing impacts future funding rounds and investor relations.
- Clinical Efficacy
- The pace at which NFL-102 demonstrates efficacy in human trials, given its promising preclinical results.
Related topics